Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
| Autor: | Betty M. Tijms, Eline A.J. Willemse, Pieter Jelle Visser, Flora H. Duits, Wiesje M. van der Flier, Kirsten E. J. Wesenhagen, Charlotte E. Teunissen, Emma E. Wolters, Laura Ekblad, Philip Scheltens |
|---|---|
| Přispěvatelé: | RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, Neurology, Amsterdam Neuroscience - Neurodegeneration, Laboratory Medicine, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Neuroscience - Brain Imaging, APH - Personalized Medicine, APH - Methodology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
NATIONAL INSTITUTE medicine.medical_specialty Neurology diagnosis Cognitive Neuroscience ACCURACY CSF BIOMARKERS markers tau Proteins Disease decline lcsh:RC346-429 lcsh:RC321-571 csf tau Gaussian mixture modelling Cerebrospinal fluid Alzheimer Disease Normal cognition CEREBROSPINAL-FLUID BIOMARKER Internal medicine mental disorders medicine Humans Dementia Mixture modelling Cognitive Dysfunction lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry lcsh:Neurology. Diseases of the nervous system Amyloid beta-Peptides business.industry Research DEMENTIA SIGNATURE Alzheimer's disease medicine.disease Prognosis Peptide Fragments PATHOLOGY Cohort Disease Progression Biomarker (medicine) Neurology (clinical) business Alzheimer’s disease Biomarkers |
| Zdroj: | Duits, F H, Wesenhagen, K E J, Ekblad, L, Wolters, E, Willemse, E A J, Scheltens, P, van der Flier, W M, Teunissen, C E, ADNI, Visser, P J & Tijms, B M 2021, ' Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts ', Alzheimer's Research and Therapy, vol. 13, no. 1, 2 . https://doi.org/10.1186/s13195-020-00713-3 Alzheimer's Research & Therapy Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-25 (2021) Alzheimer's Research & Therapy, 13(1):2. BioMed Central Ltd Alzheimer's Research and Therapy, 13(1):2. BioMed Central |
| ISSN: | 1758-9193 |
| DOI: | 10.1186/s13195-020-00713-3 |
| Popis: | Background As Alzheimer’s disease (AD) pathology presents decades before dementia manifests, unbiased biomarker cut-points may more closely reflect presence of pathology than clinically defined cut-points. Currently, unbiased cerebrospinal fluid (CSF) tau cut-points are lacking. Methods We investigated CSF t-tau and p-tau cut-points across the clinical spectrum using Gaussian mixture modelling, in two independent cohorts (Amsterdam Dementia Cohort and ADNI). Results Individuals with normal cognition (NC) (total n = 1111), mild cognitive impairment (MCI) (total n = 1213) and Alzheimer’s disease dementia (AD) (total n = 1524) were included. In both cohorts, four CSF t- and p-tau distributions and three corresponding cut-points were identified. Increasingly high tau subgroups were characterized by steeper MMSE decline and higher progression risk to AD (cohort/platform-dependent HR, t-tau 1.9–21.3; p-tau 2.2–9.5). Limitations The number of subjects in some subgroups and subanalyses was small, especially in the highest tau subgroup and in tau PET analyses. Conclusions In two independent cohorts, t-tau and p-tau levels showed four subgroups. Increasingly high tau subgroups were associated with faster clinical decline, suggesting our approach may aid in more precise prognoses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink